Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
At Revital Trichology and Wellness, we bring to India the cutting-edge AOD-9604 therapy, a breakthrough peptide derived from human growth hormone, engineered specifically to help: Burn fat Preserve lean muscle Reboot your metabolism All without the side effects of traditional fat-loss drugs or surgery
Brain Fog Improves cognitive clarity by supporting neurotransmitter and nerve health
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone F M Ng 1, J Sun, L Sharma, R Libinaka, W J Jiang, R Gianello Affiliations expand PMID: 11146367 DOI: 10.1159/000053183 All articles and product information on this website are for educational purposes only
